Propafenone
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Propafenone
|
|
| Systematic (IUPAC) name | |
| 1-[2-(2-hydroxy-3-propylamino-propoxy) phenyl] -3-phenyl-propan-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H27NO3 |
| Mol. mass | 341.444 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 97% |
| Metabolism | ? |
| Half life | 2-10 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Propafenone (pro-PA-fen-own) (brand name Rythmol®) is a class Ic anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.
Propafenone works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells.
Propafenone is metabolized primarily in the liver. Because of its short half-life, it requires dosing two or three times daily to maintain steady blood levels. The long-term safety of propafenone is unknown. Because it is structurally similar to another dangerous anti-arrhythmic medicine, flecainide, caution should be exercised in its use. Flecainide has been shown to increase the occurrence of dangerous arrhythmias, primarily in patients with underlying heart disease.
Side effects attributed to propafenone include hypersensitivity reactions, lupus-like syndrome, agranulocytopenia, CNS disturbances such as dizziness, lightheadedness, G.I. upset, metallic taste and bronchospasm.
The patents for the Rythmol family of products are owned by Reliant Pharmaceuticals Inc. in Liberty Corner, N.J. It acquired the patents from developer Abbott Laboratories Inc. in 2003.
Reliant Pharmaceuticals filed a federal patent infringement lawsuit against generic drug maker Par Pharmaceuticals Inc. on December 19, 2006. The lawsuit, filed in Delaware district court, seeks to prevent Par from manufacturing a generic version of Rythmol. Par is seeking approval to do so from the U.S. Food and Drug Administration.
Reliant's patent for the drug was issued in October 1997 and expires in 2014. Par believes the patent is invalid, according to its filing with the FDA.
[edit] External links
- Rythmol (manufacturer's website)
- Propafenone (patient information)
|
|
|
|---|---|
| class Ia | Ajmaline, Disopyramide, Prajmaline, Procainamide, Quinidine, Sparteine |
| class Ib | Aprindine, Lidocaine, Mexiletine, Tocainide |
| class Ic | Encainide, Flecainide, Lorcainide, Moricizine, Propafenone |
| class II | Propranolol, Metoprolol, Nadolol, Atenolol, Acebutolol, Pindolol see Beta blockers (C07) |
| class III | Amiodarone, Bretylium tosylate, Bunaftine, Dofetilide, Ibutilide, Sotalol |
| class IV | Verapamil, Diltiazem see Calcium channel blockers (C08) |
| class V | Adenosine, Atropine, Digoxin |
